Stocktoria
Emergent BioSolutions Inc. EBS
NYSE · XNYS · stock · Pharmaceutical Preparations · website · IPO 2006-11-15
Emergent BioSolutions Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | — | — | 30.3% | 34.3% | 50.3% |
| Operating margin | 13.5% | -10.4% | -69.2% | -15.2% | 19.2% |
| Net margin | 7.1% | -18.3% | -72.5% | -18.9% | 12.4% |
| FCF margin | 21.1% | 3.4% | -24.6% | -13.4% | 5.4% |
| Return on assets | 4.0% | -13.7% | -41.7% | -6.7% | 7.4% |
| Return on equity | 10.1% | -39.5% | -117.1% | -15.2% | 13.6% |
| Debt / equity | 1.13× | 1.45× | 1.34× | 1.02× | 0.53× |
| Current ratio | 5.01 | 3.69 | 1.04 | 0.98 | 3.40 |
| Revenue growth | -28.8% | -0.5% | -6.1% | -37.0% | 14.0% |
Source: SEC EDGAR filings · CIK 0001367644 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.